Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.75
-2.5%
$5.99
$3.93
$7.32
$294.17M1.55682,654 shs7.02 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.41
+1.6%
$6.36
$4.58
$9.78
$371.54M1.85514,411 shs1.89 million shs
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
$22.93
+0.6%
$22.54
$2.50
$22.94
$71.77M0.1419,700 shs50,800 shs
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$27.49
+0.6%
$25.00
$18.35
$35.00
$329.06M0.9434,025 shs269,597 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%-2.38%-6.35%+20.80%+35.61%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+16.33%+22.28%+21.88%+7.24%
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
0.00%0.00%0.00%0.00%0.00%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
0.00%+14.30%+11.61%+37.93%+16.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.9012 of 5 stars
3.52.00.04.51.52.50.0
CryoPort, Inc. stock logo
CYRX
CryoPort
3.4751 of 5 stars
4.42.00.00.01.93.30.6
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
4.3928 of 5 stars
3.54.00.03.02.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.00
Buy$19.25234.78% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0048.45% Upside
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
0.00
N/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
3.00
Buy$69.50152.82% Upside

Current Analyst Ratings Breakdown

Latest LABP, ABEO, CYRX, and XOMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$19.00
5/28/2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00
5/16/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $20.00
5/15/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/30/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $20.00
4/17/2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$3.50M84.05N/AN/A$1.01 per share5.69
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.63N/AN/A$7.44 per share1.00
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
$18M3.99N/AN/A$7.41 per share3.09
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$28.49M11.55N/AN/A$6.95 per share3.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$63.73M-$1.27N/AN/AN/AN/A-118.82%-52.48%8/11/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
-$21.93M-$3.99N/AN/AN/AN/A-73.00%-63.00%N/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)

Latest LABP, ABEO, CYRX, and XOMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.35-$0.24+$0.11-$0.24N/AN/A
5/13/2025Q1 2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
N/AN/AN/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.27
4.90
4.90
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
N/A
4.43
4.43
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1.18
5.54
5.54

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
49.06%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
95.92%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
5.40%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
1.30%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/A51.16 million48.40 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
193.13 million3.09 millionNot Optionable
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1011.97 million11.11 millionOptionable

Recent News About These Companies

XOMA Royalty to Buy Turnstone Biologics
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$5.75 -0.15 (-2.54%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$5.56 -0.19 (-3.29%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.41 +0.12 (+1.65%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$7.42 +0.01 (+0.13%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Landos Biopharma stock logo

Landos Biopharma NASDAQ:LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

XOMA Royalty stock logo

XOMA Royalty NASDAQ:XOMA

$27.49 +0.17 (+0.62%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$27.55 +0.06 (+0.22%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.